276 related articles for article (PubMed ID: 30717691)
21. A randomized trial of JTT-751 versus sevelamer hydrochloride in patients on hemodialysis.
Yokoyama K; Akiba T; Fukagawa M; Nakayama M; Sawada K; Kumagai Y; Chertow GM; Hirakata H
Nephrol Dial Transplant; 2014 May; 29(5):1053-60. PubMed ID: 24376274
[TBL] [Abstract][Full Text] [Related]
22. Implementation and effectiveness of an intensive education program on phosphate control among hemodialysis patients: a non-randomized, single-arm, single-center trial.
Yin J; Yin J; Lian R; Li P; Zheng J
BMC Nephrol; 2021 Jul; 22(1):243. PubMed ID: 34210293
[TBL] [Abstract][Full Text] [Related]
23. Pharmacology, efficacy and safety of oral phosphate binders.
Hutchison AJ; Smith CP; Brenchley PE
Nat Rev Nephrol; 2011 Sep; 7(10):578-89. PubMed ID: 21894188
[TBL] [Abstract][Full Text] [Related]
24. A Randomized Trial on the Effect of Phosphate Reduction on Vascular End Points in CKD (IMPROVE-CKD).
Toussaint ND; Pedagogos E; Lioufas NM; Elder GJ; Pascoe EM; Badve SV; Valks A; Block GA; Boudville N; Cameron JD; Campbell KL; Chen SSM; Faull RJ; Holt SG; Jackson D; Jardine MJ; Johnson DW; Kerr PG; Lau KK; Hooi LS; Narayan O; Perkovic V; Polkinghorne KR; Pollock CA; Reidlinger D; Robison L; Smith ER; Walker RJ; Wang AYM; Hawley CM;
J Am Soc Nephrol; 2020 Nov; 31(11):2653-2666. PubMed ID: 32917784
[TBL] [Abstract][Full Text] [Related]
25. A Randomized Trial of Tenapanor and Phosphate Binders as a Dual-Mechanism Treatment for Hyperphosphatemia in Patients on Maintenance Dialysis (AMPLIFY).
Pergola PE; Rosenbaum DP; Yang Y; Chertow GM
J Am Soc Nephrol; 2021 Jun; 32(6):1465-1473. PubMed ID: 33766811
[TBL] [Abstract][Full Text] [Related]
26. Phosphate balance in ESRD: diet, dialysis and binders against the low evident masked pool.
Galassi A; Cupisti A; Santoro A; Cozzolino M
J Nephrol; 2015 Aug; 28(4):415-29. PubMed ID: 25245472
[TBL] [Abstract][Full Text] [Related]
27. One year efficacy and safety of lanthanum carbonate for hyperphosphatemia in Japanese chronic kidney disease patients undergoing hemodialysis.
Shigematsu T;
Ther Apher Dial; 2010 Feb; 14(1):12-9. PubMed ID: 20438515
[TBL] [Abstract][Full Text] [Related]
28. A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data.
St Peter WL; Liu J; Weinhandl E; Fan Q
Am J Kidney Dis; 2008 Mar; 51(3):445-54. PubMed ID: 18295060
[TBL] [Abstract][Full Text] [Related]
29. Assessment of survival in a 2-year comparative study of lanthanum carbonate versus standard therapy.
Wilson R; Zhang P; Smyth M; Pratt R
Curr Med Res Opin; 2009 Dec; 25(12):3021-8. PubMed ID: 19845495
[TBL] [Abstract][Full Text] [Related]
30. Lanthanum carbonate: a postmarketing observational study of efficacy and safety.
Rombolà G; Londrino F; Corbani V; Falqui V; Ardini M; Zattera T;
J Nephrol; 2012; 25(4):490-6. PubMed ID: 22476966
[TBL] [Abstract][Full Text] [Related]
31. The economic impact of improving phosphate binder therapy adherence and attainment of guideline phosphorus goals in hemodialysis patients: a Medicare cost-offset model.
Ramakrishnan K; Braunhofer P; Newsome B; Lubeck D; Wang S; Deuson J; Claxton AJ
Adv Ther; 2014 Dec; 31(12):1272-86. PubMed ID: 25479935
[TBL] [Abstract][Full Text] [Related]
32. Comparison of efficacy of the phosphate binders nicotinic acid and sevelamer hydrochloride in hemodialysis patients.
Ahmadi F; Shamekhi F; Lessan-Pezeshki M; Khatami MR
Saudi J Kidney Dis Transpl; 2012 Sep; 23(5):934-8. PubMed ID: 22982903
[TBL] [Abstract][Full Text] [Related]
33. Clinical efficacy and cost-effectiveness of lanthanum carbonate as second-line therapy in hemodialysis patients in Japan.
Goto S; Komaba H; Moriwaki K; Fujimori A; Shibuya K; Nishioka M; Kim JI; Yoshiya K; Shin J; Hasegawa H; Taniguchi M; Fujii H; Nishi S; Kamae I; Fukagawa M
Clin J Am Soc Nephrol; 2011 Jun; 6(6):1375-84. PubMed ID: 21551021
[TBL] [Abstract][Full Text] [Related]
34. Clinical usefulness of lanthanum carbonate for serum phosphate control in difficult patients.
Almirall J; Betancourt L; Esteve V; Valenzuela MP; López T; Ruiz A; Martínez-Ocaña JC; Calvet X
Int Urol Nephrol; 2012 Feb; 44(1):231-6. PubMed ID: 21069570
[TBL] [Abstract][Full Text] [Related]
35. Effect of Treating Hyperphosphatemia With Lanthanum Carbonate vs Calcium Carbonate on Cardiovascular Events in Patients With Chronic Kidney Disease Undergoing Hemodialysis: The LANDMARK Randomized Clinical Trial.
Ogata H; Fukagawa M; Hirakata H; Kagimura T; Fukushima M; Akizawa T;
JAMA; 2021 May; 325(19):1946-1954. PubMed ID: 34003226
[TBL] [Abstract][Full Text] [Related]
36. [Treatment of hyperphosphatemia with sevelamer in patients with chronic renal failure].
Suñer M; Guerrero A; Montes R; Rivera M; Ruiz A; Martínez-García M; Pérez-Valdivia MA; Mateos J
Nefrologia; 2004; 24(2):142-8. PubMed ID: 15219089
[TBL] [Abstract][Full Text] [Related]
37. A Review of Phosphate Binders in Chronic Kidney Disease: Incremental Progress or Just Higher Costs?
St. Peter WL; Wazny LD; Weinhandl E; Cardone KE; Hudson JQ
Drugs; 2017 Jul; 77(11):1155-1186. PubMed ID: 28584909
[TBL] [Abstract][Full Text] [Related]
38. A meta-analysis of phosphate binders lanthanum carbonate versus sevelamer hydrochloride in patients with end-stage renal disease undergoing hemodialysis.
Zhou T; Li H; Xie W; Lin Z
Afr Health Sci; 2018 Sep; 18(3):689-696. PubMed ID: 30603002
[TBL] [Abstract][Full Text] [Related]
39. Design and baseline characteristics of the LANDMARK study.
Ogata H; Fukagawa M; Hirakata H; Kaneda H; Kagimura T; Akizawa T;
Clin Exp Nephrol; 2017 Jun; 21(3):531-537. PubMed ID: 27405619
[TBL] [Abstract][Full Text] [Related]
40. Effect of lanthanum carbonate on phosphate control in continuous ambulatory peritoneal dialysis patients in Korea: a randomized prospective study.
Lee YK; Choi HY; Shin SK; Lee HY
Clin Nephrol; 2013 Feb; 79(2):136-42. PubMed ID: 23211335
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
